F10 and intracerebral hemorrhage: Different studies have shown that in cases of major bleeding related to the use of FXais, the use of andexanet alfa can reduce anti-FXa activity, with high hemostatic efficacy in most subjects [34], including a prospective, randomized trial comparing andexanet alfa to usual care (mostly PCCs), resulting in improved hemostatic efficacy and better control of hematoma expansion in FXa inhibitor-related intracerebral hemorrhage [35].